You’ve already googled this. Every article either reads like a pharma pamphlet or hides the price, and you still don’t know whether to ask your provider for Zepbound, Wegovy, the new pill that just got approved, the compounded version your friend takes, or to hold out for the 28% weight loss drug everyone’s talking about.
There is no single best GLP-1 medication in 2026. There are four winners on four different axes.
Tirzepatide leads on weight loss. In SURMOUNT-5, the first head-to-head trial, it produced 20.2% average loss vs 13.7% for semaglutide over 72 weeks. Semaglutide leads on cardiovascular evidence. The SELECT trial showed a 20% reduction in major cardiac events across 17,604 non-diabetic patients with established heart disease. Foundayo (orforglipron), FDA-approved April 1, 2026, leads on convenience as the first oral GLP-1 that works at weight-loss doses with no food, water, or timing restrictions. Compounded tirzepatide leads on cost at $99 to $149/month vs $299 to $449 for branded.
Retatrutide will eventually beat all of them on raw weight loss (28.3% in TRIUMPH-1), but FDA approval is mid-to-late 2027. We’ll cover whether to wait.
Food noise, the persistent intrusive thoughts about food that show up regardless of actual hunger, is one of the things every one of these drugs treats. One survey found 62% of users reported constant food-related thoughts before semaglutide; after, 16%. The mechanism runs through the nucleus accumbens, the brain’s reward hub. We’ll come back to how each drug compares on that.
Here’s how the seven medications we’d actually consider stack up.
Top Picks Comparison Table
| Path | Best For | Starting Price | Patient-First Score | Apply Now |
|---|---|---|---|---|
| Tirzepatide (Zepbound, Mounjaro, compounded) | most weight loss, lowest nausea | — | — | — |
| Semaglutide (Wegovy, Ozempic, compounded) | pick this if you have heart disease history | — | — | — |
| Found | the only pill that works at weight-loss doses | — | 10 / 100 | See Offer |
| Compounded tirzepatide and semaglutide | the cost path most readers will actually use | $86/mo | — | — |
| Liraglutide (Saxenda) | older, weaker, only one fit left | $125/mo | — | — |
| Retatrutide | 28% weight loss, but you’ll wait until 2027 | — | — | — |
1. Tirzepatide (Zepbound, Mounjaro, compounded): most weight loss, lowest nausea
The drug that produces more weight loss also makes fewer people sick. In SURMOUNT-5, tirzepatide hit 20.2% average loss over 72 weeks vs semaglutide’s 13.7%, with GI-related discontinuation of 2.7% vs 5.6%. That’s not a tradeoff between efficacy and tolerability. It’s both, in the same molecule.
Tirzepatide is a dual GLP-1 and GIP receptor agonist. The GIP component is why nausea is lower. In preclinical models documented in PMC12175907, GIP receptor agonism attenuates the nausea and emesis that pure GLP-1 agonists like semaglutide produce. In shrew emesis models, tirzepatide showed complete absence of vomiting at all tested doses while semaglutide caused dose-dependent emesis.
The patient experience matches the trial data. MintArrow, a blogger who lost 40 lbs on compounded tirzepatide, described semaglutide as “lying on the couch feeling exactly like a first trimester pregnant woman, extremely nauseated and extremely exhausted.” After switching to tirzepatide: “Not only did I feel great, I somehow had added energy. Zero nausea. And it started working FAST.” A registered dietitian quoted by Fella Health put it differently: “I’m just not hungry in my head in between, and I’m not thinking about food in terms of what’s the tastiest or what do I want.”
There’s a qualitative difference vs semaglutide that shows up across patient accounts. On semaglutide, many users describe food as actively unappealing. On tirzepatide, users report still wanting salad, burger, ice cream, just in smaller portions.
Effectiveness with numbers: SURMOUNT-1 produced 16.0% loss at 5mg, 21.4% at 10mg, and 22.5% at 15mg over 72 weeks. More than 60% of the 15mg group achieved at least 20% body weight reduction.
Side effects, week by week: Fella Health aggregate data puts nausea at 20-30% in weeks 1-4, peaking 1-3 days post-injection then fading. Diarrhea 18-24%, vomiting 8-12%, constipation 16-21%. Side effects diminish at stable doses. SURMOUNT-1 GI discontinuation was 14.3-16.4% across doses, but 26.4% of the placebo group also discontinued, which suggests trial attrition captured more than pure GI dropout. Hair loss is documented in patient reports, generally temporary and tied to rapid weight loss rather than the drug directly.
Cost, three paths: – Insured with savings card: roughly $25/month if Zepbound is covered. – LillyDirect self-pay vials: $299 (2.5mg), $399 (5mg), $449 (7.5mg to 15mg) within a 45-day refill window. Outside that window, 12.5mg jumps to $849 and 15mg to $1,049. – Compounded 503A: $125/month flat at Trimi, $99-$169/month at Henry Meds (dose-variable).
Annual gap between compounded and LillyDirect at maintenance dose: $2,400 to $3,960.
Best for: Anyone who wants maximum weight loss, anyone who quit semaglutide because of nausea, anyone willing to do a weekly injection.
Skip if: You have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (boxed warning applies to all GLP-1s), you’re needle-averse with no compounded provider in budget reach, or you have no insurance and no room for $99-$125/month.
2. Semaglutide (Wegovy, Ozempic, compounded): pick this if you have heart disease history
Semaglutide isn’t the most effective GLP-1 anymore. For one specific patient, it’s still the right answer.
That patient has cardiovascular disease. The SELECT trial randomized 17,604 non-diabetic adults aged 45+ with BMI ≥27 and established CVD to semaglutide 2.4mg or placebo. Over up to 5 years, semaglutide reduced MACE (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% vs placebo. All three components contributed. Roughly 33% of that benefit was mediated through waist circumference reduction; the other ~67% was independent of weight loss itself. Tirzepatide has no equivalent trial.
Semaglutide is a pure GLP-1 agonist, once-weekly injection as Wegovy (weight loss label) or Ozempic (diabetes label). It has the longest real-world safety record of the modern GLP-1s. Ozempic has been on the market since 2017.
The food noise effect is real and well-documented. Meranda Hall, a law firm administrator, weighed 271 lbs in August 2023 and lost 78 lbs in nine months on Wegovy. “My whole life was thinking about food,” she said. The intrusive eating thoughts disappeared. Kimberly Chauche, a corporate secretary in Lincoln NE, put it this way: “All of a sudden it was like some part of my brain that was always there just went quiet.” She lost nearly 20 lbs in two months. The Couture Medspa survey found the share of users with constant food-related thoughts dropped from 62% to 16% after starting semaglutide.
Effectiveness: STEP-1 produced 14.9% average loss at 68 weeks, with 83% of participants hitting at least 5%. SURMOUNT-5 head-to-head: 13.7%.
Side effects: Higher than tirzepatide, and it’s worth being direct about this. Nausea hits 33.7% at the 2.4mg Wegovy dose vs 13.2-19.2% on tirzepatide 10mg. Vomiting 21.8% vs 2.5-8.5%. GI-related discontinuation in SURMOUNT-5: 5.6% vs 2.7%. This is the real cost of choosing semaglutide for the CV benefit.
Cost, three paths: – Insured with savings card: about $25/month if covered. – NovoCare self-pay Wegovy: $349/month for all doses, reduced in November 2025 from $499. New patients pay $199/month for the first two months at the lowest two doses. – Compounded sema: Ozari Health $86/month, Henry Meds $149/month.
A caveat on compounded semaglutide: the regulatory basis is shakier than for compounded tirzepatide because semaglutide’s FDA shortage formally ended in February 2025. The 503A patient-specific pathway remains legal, but the legal ground is thinner. More on that in the compounded section.
Quick verdict: Pick semaglutide if you have established CVD or strong CV risk factors. Pick tirzepatide if you don’t and want better weight loss with less nausea. Pick compounded semaglutide if budget is the binding constraint and you can live with the regulatory uncertainty.
3. Foundayo (orforglipron): the only pill that works at weight-loss doses
The pill we’ve been waiting for finally exists, and it does not require you to take it at 6am on an empty stomach with 4 ounces of water and then wait 30 minutes before anything else. Foundayo was FDA-approved April 1, 2026 under the National Priority Voucher program. Once daily, any time of day, no food restrictions, no water restrictions, room temperature storage.
The structural reason it works orally where Rybelsus barely does: Foundayo is a small-molecule GLP-1 agonist, not a peptide. Small molecules survive oral absorption without needing the specialized SNAC delivery vehicle that limits semaglutide’s oral bioavailability. That difference is why Foundayo can be dosed once daily at any time without the empty-stomach choreography Rybelsus demands.
Effectiveness, honestly: ATTAIN-1 phase 3 tested the 36mg dose. Result: 11.2% average weight loss at 72 weeks vs 2.1% placebo. 54.6% hit ≥10%, 36% hit ≥15%, 18.4% hit ≥20%. Compare directly: tirzepatide 20.2%, semaglutide 14.9%. For a 200 lb person, that’s roughly 18 fewer pounds than tirzepatide.
There’s an additional caveat. ATTAIN-1 used a 36mg capsule formulation. The FDA approved tablet doses up to 17.2mg only. Real-world weight loss at approved doses may be modestly lower than the trial headline number.
The switching use case: ATTAIN-MAINTAIN enrolled 376 participants previously on injectable Wegovy or Mounjaro and moved them to orforglipron for 52 weeks. Average regain: 0.9 kg, vs the roughly two-thirds regain expected with full discontinuation. For patients who hit their target on an injectable and want off the needle without losing ground, this is the legitimate path.
Side effects: Discontinuation 5.3-10.3% across orforglipron groups vs 2.7% placebo, higher than tirzepatide. Nausea, diarrhea, and constipation are the most common GI complaints, with rates roughly between tirzepatide and semaglutide. Hair loss is listed as common. Same thyroid C-cell tumor boxed warning as the injectables. No long-term CV outcomes data yet, which matters if you’re choosing primarily for cardiac protection (semaglutide remains the answer there).
Cost: Price was not yet published as of late May 2026. Based on Lilly’s branded GLP-1 pricing pattern, expect somewhere between NovoCare’s $349 Wegovy and LillyDirect’s $449 Zepbound vials. Insurance coverage will likely follow the same prior-authorization pattern as Zepbound, and savings-card programs are expected at launch.
If you would inject tirzepatide if you could, do that. If you’ve ruled injections out for any reason (phobia, travel, schedule, or hitting maintenance after a stretch on Wegovy or Mounjaro), Foundayo is the credible oral option in 2026. That wasn’t true 18 months ago.
4. Compounded tirzepatide and semaglutide: the cost path most readers will actually use
Compounded GLP-1s are still legal in May 2026, despite what you’ve read. The regulatory story has two pathways and they have different futures.
503B large-scale outsourcing facilities are largely shut out. FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, with the comment period running through June 29, 2026. FDA issued a warning letter to a 503B compounding pharmacy on May 18, 2026 for producing tirzepatide after the shortage ended. Earlier in 2026, FDA sent warning letters to 30+ compounded GLP-1 companies. Hims exited the compounded GLP-1 market.
503A patient-specific compounding pharmacies remain fully legal. Section 503A of the Federal Food, Drug, and Cosmetic Act allows pharmacies to compound a drug for an individual patient based on a valid prescription, under state pharmacy board oversight, regardless of shortage status. Trimi, Henry Meds, Ozari Health, Ro, and most reputable telehealth providers use 503A pharmacies. The question to ask your provider: is your compounding pharmacy a 503A facility?
The cost case: – Ozari Health compounded semaglutide: $86/month – Trimi compounded tirzepatide: $125/month flat (no dose-based pricing) – Henry Meds compounded tirzepatide: $99 to $169/month
Compare to LillyDirect Zepbound at $299-$449 and NovoCare Wegovy at $349. Annual savings vs LillyDirect at maintenance dose: $2,400 to $3,960.
Microdosing, the strategy no competitor covers: Compounded vials let you dose at increments the branded auto-pens can’t. Some patients start as low as 0.25 to 1mg weekly tirzepatide vs the 2.5mg standard starting dose. Titration spans 6-12 weeks rather than the standard 2-4. Weeks 1-2 produce subtle appetite suppression. Weeks 3-4 bring 1-2 lbs of loss with stable digestion. Week 5 and beyond, noticeable fat loss begins.
Microdosing fits four reader profiles: first-time GLP-1 users, anyone with sensitive digestion, low-BMI patients who don’t need aggressive titration, and patients with needle anxiety. The MintArrow case is the concrete example: 40 lbs lost on compounded tirzepatide held at 2.5mg, never escalated, maintained for 16 months. No clinical trial data exists below 2.5mg, but the anecdotal telehealth data is consistent.
Quality signals to look for: PCAB accreditation or active state board pharmacy license. Avoid any provider priced below $75/month, which is below the legitimate cost of producing the medication. Avoid overseas peptide sellers entirely. That’s a different category and isn’t legal medical compounding under US law.
What we won’t pretend away: Compounded versions are not FDA-approved finished drug products. You get a vial and an insulin syringe, not an auto-pen. The regulatory landscape may narrow further. Compounded semaglutide’s legal footing is shakier than compounded tirzepatide because semaglutide’s shortage ended earlier.
The verdict: For the patient self-paying out of pocket who doesn’t qualify for or can’t access LillyDirect or NovoCare, compounded tirzepatide via a 503A pharmacy is the highest-value GLP-1 in 2026, provided you’re willing to vet the pharmacy.
5. Oral semaglutide (Rybelsus and the Wegovy pill): mostly the wrong choice
Patients hear “oral semaglutide” and assume it’s Wegovy in pill form. It isn’t, and the version that’s actually approved barely does anything for weight loss.
Rybelsus is oral semaglutide at 7mg or 14mg, FDA-approved for type 2 diabetes only. In PIONEER trials, the 14mg dose produced about 4.5% weight loss at 26 weeks. Off-label use for weight loss exists, but at doses too low to do what injectable Wegovy does. For a 200 lb patient, 4.5% is 9 lbs over six months. Compare to tirzepatide’s 20.2% (40 lbs) or Foundayo’s 11.2% (22 lbs) over similar timeframes.
The dose problem: The OASIS-1 trial tested oral semaglutide at 50mg and achieved 15-20% weight loss, comparable to injectable Wegovy. That dose isn’t approved and isn’t commercially available in the US as of May 2026. The “Wegovy pill” that’s been in the news is essentially this higher-dose formulation awaiting FDA approval. Until it lands, the only oral semaglutide you can actually get is sub-therapeutic for weight loss.
The timing problem: Rybelsus has to be taken on an empty stomach, with no more than 4 ounces of water, and you can’t eat, drink, or take other medication for 30 minutes after. That makes it harder to take consistently than the weekly injection, and considerably harder than Foundayo, which has none of those restrictions. Patients who miss the morning window often skip the dose entirely, which means real-world weight loss tends to underperform even the modest trial numbers.
Cost: Roughly $1,000/month retail without coverage. Some insurance plans cover it for diabetes, where the price drops to standard copay territory. As a self-pay weight-loss option it’s the worst value in the GLP-1 market.
If you want an oral GLP-1 in 2026, ask about Foundayo. The narrow exception: if you have type 2 diabetes that needs treatment and weight loss is the secondary goal, Rybelsus is a reasonable diabetes medication that comes with modest weight benefit. Outside that one scenario, this is the wrong choice.
6. Liraglutide (Saxenda): older, weaker, only one fit left
Saxenda was the first GLP-1 approved for weight loss, back in 2014. It has been thoroughly outclassed since.
Saxenda is a daily subcutaneous injection of liraglutide. Average weight loss in the SCALE trials: roughly 5-8% over 56 weeks. That’s about a third of what tirzepatide does and roughly half of what semaglutide does.
It still has one defensible use case. FDA approval for adolescents aged 12 to 17 with obesity is currently limited to Saxenda among the newer GLP-1s; the weekly options haven’t been approved for that age group. For an adolescent patient with a clinical reason to start a GLP-1, Saxenda may be the only on-label option.
Some adults also prefer daily dosing for psychological reasons. Lower per-dose stakes, easier to skip a day when traveling. We don’t think that’s enough reason to choose 5-8% loss over 20%.
The downsides stack up. Daily injection instead of weekly. Higher cumulative side effect exposure. Cost is roughly similar to other branded GLP-1s without comparable efficacy. Compounded liraglutide exists but makes even less sense, because compounded tirzepatide at $125/month produces dramatically more weight loss for similar money.
Skip Saxenda unless you have a defined clinical reason to be on daily liraglutide specifically. For every other patient, tirzepatide or semaglutide is a better answer at any budget tier.
7. Retatrutide: 28% weight loss, but you’ll wait until 2027
The headline is real. Eli Lilly announced TRIUMPH-1 phase 3 results on May 21, 2026: retatrutide 12mg produced 28.3% average weight loss at 80 weeks. In the BMI ≥35 subgroup, average loss reached 30.3% (about 85 lbs) at 104 weeks. That’s higher than any approved drug has ever produced.
Retatrutide is a triple agonist. It activates GLP-1, GIP, and glucagon receptors. The glucagon component is the new mechanism vs tirzepatide’s dual GLP-1/GIP activity. The hypothesis is additional metabolic benefit through increased energy expenditure, though it adds complexity to the safety picture.
Timeline reality: Not FDA-approved. NDA filing expected late 2026 or early 2027 after the remaining TRIUMPH trials read out. Earliest realistic FDA decision: mid-to-late 2027. That’s 12 to 18 months of waiting if everything goes smoothly, and FDA timelines rarely go smoothly. Insurance coverage and pricing will take additional months after approval to stabilize.
Safety question: Phase 2 trials reported a 20% dropout rate at higher doses. Phase 3 looked better at moderate doses: the 4mg arm produced 19.0% weight loss with discontinuation lower than placebo. No CV outcomes data yet, and the glucagon receptor activation is genuinely novel territory for chronic weight-loss use.
The decision: Don’t wait. Start tirzepatide now, or compounded tirzepatide if budget requires. Twelve to eighteen months of meaningful weight loss is worth more than holding out for a drug that might be 8 percentage points more effective. If retatrutide gets approved and outperforms tirzepatide in real-world use, switching is straightforward: one week off the current drug, then start retatrutide at its starting dose. That’s the same protocol we describe in the FAQ for switching from semaglutide to tirzepatide. Among the choices available today, the best GLP-1 medication for a patient who wants maximum weight loss is still tirzepatide.
Frequently asked questions
I’m on Ozempic and want to switch to Zepbound. How do I do it safely?
Take your last Ozempic dose on its normal scheduled day, wait exactly one full week (both drugs have ~7-day half-lives), and start Zepbound at 2.5mg regardless of your prior Ozempic dose. Don’t overlap the two. Additive GLP-1 stimulation causes severe nausea, vomiting, and dehydration. SURMOUNT-5 found tirzepatide produces 47% more weight loss than semaglutide, so the switch is well-supported by direct trial evidence.
Are compounded GLP-1s still legal in May 2026?
Yes, if filled through a 503A patient-specific compounding pharmacy. 503B large-scale outsourcing is effectively closed following FDA’s April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. 503A pharmacies remain legal under Section 503A of the FD&C Act because each compound is prepared per individual prescription. Ask your telehealth provider to confirm their pharmacy is 503A.
What’s the difference between Mounjaro and Zepbound?
Same drug (tirzepatide), same doses, same manufacturer (Eli Lilly). Mounjaro is FDA-labeled for type 2 diabetes; Zepbound is FDA-labeled for weight management. The labeling difference matters for insurance coverage and for which one your provider can prescribe on-label. Ozempic/Wegovy (semaglutide) is the parallel diabetes/weight-loss brand pair.
If I stop taking my GLP-1, will I gain the weight back?
Most people regain significant weight. SURMOUNT-4 found 14% average regain within 52 weeks of stopping tirzepatide. The STEP-1 extension showed 11.6 percentage points regained by one year off semaglutide. An Oxford BMJ 2025 analysis of 9,000+ patients projected return to starting weight in about 1.7 years, with regain happening roughly 4x faster than after conventional dieting. Treat these as long-term medications, not 6-month interventions.
What does the first week on tirzepatide actually feel like?
Tolerability, not transformation. Starting dose is 2.5mg. Expect 0-3 lbs of mostly water and gut content loss. Nausea hits 12-20% of patients, peaks 1-3 days post-injection, then improves. Appetite changes may begin within the first 1-2 weeks but aren’t guaranteed. Real food noise reduction and meaningful weight loss typically show up between weeks 3 and 8.
I have a history of cardiovascular disease. Does that change which GLP-1 to take?
Yes. Semaglutide (Wegovy 2.4mg) is the only GLP-1 with proven cardiovascular outcomes data in non-diabetic patients. SELECT showed a 20% MACE reduction in 17,604 patients with established CVD over up to 5 years. Tirzepatide has no equivalent trial. For patients with prior MI, stroke, or documented atherosclerotic CVD, cardiologists often prefer semaglutide despite tirzepatide’s better weight loss profile. Discuss with your cardiologist.
I tried semaglutide and couldn’t handle the nausea. Is tirzepatide really different?
Meaningfully different. Head-to-head: vomiting 2.5-8.5% on tirzepatide 10mg vs 21.8% on semaglutide 2.4mg. Nausea 13.2-19.2% vs 33.7%. The mechanism is GIP receptor agonism, which provides an antiemetic effect against GLP-1-induced nausea. In preclinical shrew emesis models, tirzepatide showed complete absence of vomiting at all tested doses. Many patients who quit semaglutide tolerate tirzepatide without GI symptoms.